As expected, during the establishment of the model, we observed a gradual increase in BP during the course of pregnancy and a hypotensive effect in the L-NAME group, which was derived from both the administration of the hydralazine, which is an agent that is known for its antihypertensive properties [21], and from the administration of FGF2, which may also regulate hypertension [12,22]. The gene discussed is FGF2; the disease is hypertensive disorder.